Trials / Conditions / Astrocytoma, IDH-Mutant, Grade 3
Astrocytoma, IDH-Mutant, Grade 3
4 registered clinical trials studyying Astrocytoma, IDH-Mutant, Grade 3 — 3 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Not Yet Recruiting | Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas NCT07468136 | Mayo Clinic | Phase 1 / Phase 2 |
| Not Yet Recruiting | Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cance NCT07215910 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Recruiting | SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) NCT05303519 | Nuvation Bio Inc. | Phase 3 |
| Active Not Recruiting | Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytom NCT03528642 | National Cancer Institute (NCI) | Phase 1 |